20.01.2020
- Bayer has run into difficulty with healthcare providers in England and Germany over the high cost of the German group’s new “tissue-agnostic” cancer drug Vitrakvi, which was...
09.01.2019
- In the latest move by “big pharma” to buy into cancer-focused biotechs, US drugmaker Eli Lilly is acquiring Loxo Oncology for about $8 billion in cash. The plans were announced on...
05.12.2018
- A new type of cancer treatment developed by a partnership of Bayer with biotech partner Loxo Oncology has won approval from the US Food and Drug Administration (FDA). Vitrakvi is...
